Premium
Partnership between academia and industry for drug discovery in Alzheimer's disease
Author(s) -
Ivinson Adrian J.,
Lane Roger,
May Patrick C.,
Hosford David A.,
Carrillo Maria C.,
Siemers Eric R.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.02.004
Subject(s) - general partnership , drug discovery , disease , pharmaceutical industry , drug development , business , profit (economics) , drug industry , medicine , drug , political science , engineering ethics , engineering , pharmacology , economics , bioinformatics , finance , biology , pathology , microeconomics
Drug discovery has traditionally been almost exclusively the purview of pharmaceutical and biotechnology companies, whereas universities have focused on basic research. However, given the challenges involved in discovering and developing truly effective, symptomatic treatments and disease‐modifying drugs for Alzheimer's disease, there is a need to reassess this simple division of labor. Whereas each sector is likely to retain a core interest and expertise at either end of the drug discovery spectrum, there is room for closer cooperation at the intersection of the for‐profit and not‐for‐profit sectors. The Alzheimer's Association Research Roundtable convened a meeting of senior industry researchers and academic investigators to discuss this intersection and to assess the opportunity for closer partnership on Alzheimer's disease drug discovery and development.